| Patients who completed the study on 150 mg eq. throughout | Patients who did not complete the study on 150 mg eq. throughout | ||||
---|---|---|---|---|---|---|
 | Group A (N = 100) | Group B (N = 4) | Total (N = 104) | Group C (N = 86) | Group D (N = 22) | Total (N = 108) |
Total no. patients with serious TEAEs | 5 (5.0) | 0 | 5 (4.8) | 24 (27.9) | 4 (18.2) | 28 (25.9) |
Schizophrenia | 3 (3.0) | 0 | 3 (2.9) | 7 (8.1) | 1 (4.5) | 8 (7.4) |
Psychotic disorder | 1 (1.0) | 0 | 1 (1.0) | 5 (5.8) | 0 | 5 (4.6) |
Anxiety | 1 (1.0) | 0 | 1 (1.0) | 1 (1.2) | 0 | 1 (0.9) |
Hallucination, auditory | 1 (1.0) | 0 | 1 (1.0) | 1 (1.2) | 0 | 1 (0.9) |
Hallucination, tactile | 1 (1.0) | 0 | 1 (1.0) | 0 | 0 | 0 |
Agitation | 0 | 0 | 0 | 5 (5.8) | 0 | 5 (4.6) |
Insomnia | 0 | 0 | 0 | 3 (3.5) | 0 | 3 (2.8) |
Abnormal behaviour | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Aggression | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Alcohol abuse | 0 | 0 | 0 | 0 | 1 (4.5) | 1 (0.9) |
Delusion | 0 | 0 | 0 | 0 | 1 (4.5) | 1 (0.9) |
Hallucination | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Paranoia | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Psychiatric decompensation | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Schizophrenia, paranoid type | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Tremor | 0 | 0 | 0 | 2 (2.3) | 0 | 2 (1.9) |
Akathisia | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Convulsion | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Dystonia | 0 | 0 | 0 | 0 | 1 (4.5) | 1 (0.9) |
Parkinsonism | 0 | 0 | 0 | 0 | 1 (4.5) | 1 (0.9) |
Salivary hypersecretion | 0 | 0 | 0 | 2 (2.3) | 0 | 2 (1.9) |
Gastrooesophageal reflux disease | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Muscle rigidity | 0 | 0 | 0 | 2 (2.3) | 0 | 2 (1.9) |
Bradycardia | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Irritability | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Hypochloraemia | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Hyponatraemia | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (0.9) |
Pneumonia | 0 | 0 | 0 | 0 | 1 (4.5) | 1 (0.9) |